(VIANEWS) – Shares of INNATE PHARMA (CAC 40: IPH.PA) jumped by a staggering 16.2% in 5 sessions from €2.64 to €3.07 at 15:45 EST on Tuesday, after three sequential sessions in a row of gains. CAC 40 is jumping 0.58% to €7,388.70, after five successive sessions in a row of gains.
About INNATE PHARMA
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
Earnings Per Share
As for profitability, INNATE PHARMA has a trailing twelve months EPS of €-0.811.
Volume
Today’s last reported volume for INNATE PHARMA is 127937 which is 33.4% below its average volume of 188314.
Volatility
INNATE PHARMA’s last week, last month’s, and last quarter’s current intraday variation average was 4.81%, 0.32%, and 2.50%.
INNATE PHARMA’s highest amplitude of average volatility was 4.81% (last week), 2.96% (last month), and 2.50% (last quarter).
More news about INNATE PHARMA (IPH.PA).
